Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Date:6/30/2008

is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard carboplatin and paclitaxel response rates will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are cur
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
2. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
5. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
6. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
7. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, ... and corrected the multiple inaccuracies in the press ... regarding the recent rulings from the Patent Trial ...
(Date:8/27/2015)...  Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... Morgan Stanley Global Healthcare Conference on September 16, 2015, ... to listen to the live discussion via the internet ... https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay of ... conclusion of the live event and accessible via the ...
(Date:8/27/2015)... 27, 2015 Major pharmaceutical and medical device companies ... conference in Philadelphia on Oct. 20, ... Tom Hagy of HB Litigation Conferences has announced. ... website at http://litigationconferences.com/?p=31886 The program is ... & Mahoney and Michelle Hart Yeary of Dechert ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3
... Systems ( http://www.dcmsys.com ), healthcare IT company and teleradiology ... the Vendor Neutral Archive (VNA) vendor of choice by ... Dicom Systems, VNA works with any existing ... current storage to your PACS archive at any time, ...
... LANSING, Mich., Jan. 16, 2012  Neogen Corporation (NASDAQ: ... detect precise amounts of the mycotoxin zearalenone in grain ... wide variety of reproductive problems if eaten by livestock. ... to the company,s unequaled line of simple, quick, and ...
Cached Medicine Technology:ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2Neogen Develops Simple, Precise Test for Mold Toxin Zearalenone 2
(Date:8/27/2015)... ... 27, 2015 , ... In mid-May, Logistics Trust, Inc. (“Logistics ... launch of its Doobster platform, a HIPAA-compliant mobile application that allows medical marijuana ... phones and tablets. Well, Doobster, “The App That Delivers!” is here! ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Summit , scheduled for October 27-29, 2015 in San Jose, CA. The ... will primarily focus on the void that exists where battery development and energy ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
(Date:8/27/2015)... ... ... Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a ... be located at US Highway 19 North and Highlands Boulevard, less than eight miles from ... the project is slated to begin in September 2015. , The new 24-bed ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
Breaking Medicine News(10 mins):Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3
... estimate that fully 95 percent of our DNA represents ... the journal Cell researchers at The Wistar ... the discovery of the ability of long non-coding RNA ... long ncRNA molecules may represent so-called gene enhancer elementsshort ...
... used as a marker of health and well-being in unborn ... currently available to differentiate between a small, healthy fetus and ... significant limitations. What if they were improved? Would it save ... need medical intervention because their fetuses might just be small ...
... Fox Foundation for Parkinson,s Research announced awards totaling approximately ... pre-clinical therapeutic development projects. The funding includes $2.5 million ... Intervention Awards, one of the Foundation,s Edmond J. Safra ... the 2010 Clinical Intervention Awards are: , Charlotte ...
... Oct. 6, 2010 A set of proteins found ... way to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical ... An analysis of the proteins, plus a clinical exam, ... percent accurate in ruling it out in people without the ...
... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay News) -- ... received ,hands-only, cardiopulmonary resuscitation (CPR) from a bystander were ... received no CPR or conventional CPR with mouth-to-mouth breathing. ... only is ,hands-only, CPR -- in which the rescuer ...
... Mozes HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... apnea can subtly alter the shape of a patient,s face ... treatment, called continuous positive airway pressure (CPAP) can help relieve ... found possible craniofacial change [as a result of] long-term CPAP ...
Cached Medicine News:Health News:Wistar researchers discover new class of objects encoded within the genome 2Health News:Wistar researchers discover new class of objects encoded within the genome 3Health News:MFM researcher earns $3.7M NIH grant to study preterm birth 2Health News:MJFF announces over $10 million in funding for clinical and pre-clinical PD research 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 3Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 4Health News:Sleep Apnea Mask May Cause Subtle Facial Changes 2Health News:Sleep Apnea Mask May Cause Subtle Facial Changes 3
... and negative whole blood control to test ... solubility tests and hemoglobin electrophoresis. Sickle-Chex is ... manufacturers' solubility kits. Sickle-Chex is packaged in ... vial dispenses an accurate sample volume. No ...
... three-part differential control assayed for all parameters on ... Series, AcT/AcT diff/AcT diff2, MD Series and ONYX ... 1800; ABX Micros 60; and Diatron Abacus and ... stability of 30 days and a six-month closed-vial ...
... Cell-Chex Auto is a whole blood ... of hematology instruments that measure automated blood ... The assay provides total RBC and WBC ... and Sapphire, Beckman Coulter LH750/LH 755 (levels ...
iSleep 20i is an advanced high performance CPAP with outstanding self-adjusting i‑technology....
Medicine Products: